The city of Charlotte, North Carolina, currently has 75 active clinical trials seeking participants for Cancer research studies.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Research Site, Charlotte, North Carolina
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599
Recruiting
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Charlotte, North Carolina
Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer
Register for Updates
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Center for Liver Disease and Transplant at CMC, Charlotte, North Carolina
Conditions: Hepatocellular Cancer
Register for Updates
Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors
NCT06634381
Recruiting
The purpose of this research study is to better understand how cancer-related fatigue affects patients and how it's discussed with providers. This information will be used to develop an educational resource (visual aid poster) that could help individuals and their providers talk about cancer-related fatigue and which may help individuals better manage this symptom.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Levine Childrens Hospital Pediatric Cancer and Blood Disorders, Charlotte, North Carolina +1 locations
Conditions: Cancer, Fatigue
Register for Updates
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
NCT05415358
Recruiting
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Lung Cancer, Nonsmall Cell
Register for Updates
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
NCT06489041
Recruiting
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Cancer, Gastrointestinal Cancer
Register for Updates
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
NCT06866964
Recruiting
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina
Conditions: Germ Cell Tumor, Testicular Cancer
Register for Updates
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Research Site, Charlotte, North Carolina
Conditions: Breast Cancer
Register for Updates
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
NCT06607406
Recruiting
The goal of this clinical trial is to determine whether accelerated radiotherapy (involving 6 treatments per week) is better than standard radiotherapy (involving 5 treatments per week) at treating cancer of the head and neck when initiated more than 6 weeks after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma HNSCC
Register for Updates
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796
Recruiting
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Register for Updates
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324
Recruiting
The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Pancreatic Cancer, Breast Cancer
Register for Updates
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
NCT04577599
Recruiting
Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.
Gender:
ALL
Ages:
Between 40 years and 54 years
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Lung Neoplasms, Lung Cancer
Register for Updates